Valerie Wienert’s Post

🚀 The Series Continues! Up Next: Mastering the Treatment Landscape 🚀 👉https://lnkd.in/dNNE8JiS 🔍 Are you navigating your first drug launch or entering a new indication? The complexity of today's pharmaceutical market demands a deep dive into the Treatment Landscape for true success. Join us in our upcoming webinar as part of the "First Time Leading a Drug Launch" series, where we challenge traditional market analysis approaches. 🌐 Learn why moving 𝗯𝗲𝘆𝗼𝗻𝗱 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱 𝗛𝗖𝗣 𝗽𝗮𝗻𝗲𝗹𝘀 𝗮𝗻𝗱 𝘀𝗮𝗹𝗲𝘀 𝗱𝗮𝘁𝗮 is crucial with Gloria Seibert, CEO and founder of Temedica, and Ludger Kempf, Pharma Consultant at Temedica. Discover an advanced approach to unlock a holistic market understanding essential for your product launch. 🗓️ Mark your calendars for 𝗔𝗽𝗿𝗶𝗹 𝟭𝟴, 𝟭𝟰:𝟬𝟬 𝗖𝗘𝗧, and step into the future of market analysis through the lens of our Disease Navigator. The webinar is held in German, promising to be a must-attend session for every pharma leader. REGISTER NOW ✅ #launchsuccess #treatmentjourney #marketanalysisinnovation #realworldevidence #diseasenavigator

🚀 The Series Continues! Up Next: Mastering the Treatment Landscape 🚀 👉https://lnkd.in/dNNE8JiS 🔍 Are you navigating your first drug launch or entering a new indication? The complexity of today's pharmaceutical market demands a deep dive into the Treatment Landscape for true success. Join us in our upcoming webinar as part of the "First Time Leading a Drug Launch" series, where we challenge traditional market analysis approaches. 🌐 Learn why moving 𝗯𝗲𝘆𝗼𝗻𝗱 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱 𝗛𝗖𝗣 𝗽𝗮𝗻𝗲𝗹𝘀 𝗮𝗻𝗱 𝘀𝗮𝗹𝗲𝘀 𝗱𝗮𝘁𝗮 is crucial with Gloria Seibert, CEO and founder of Temedica, and Ludger Kempf, Pharma Consultant at Temedica. Discover an advanced approach to unlock a holistic market understanding essential for your product launch. 🗓️ Mark your calendars for 𝗔𝗽𝗿𝗶𝗹 𝟭𝟴, 𝟭𝟰:𝟬𝟬 𝗖𝗘𝗧, and step into the future of market analysis through the lens of our Disease Navigator. The webinar is held in German, promising to be a must-attend session for every pharma leader. REGISTER NOW ✅ #launchsuccess #treatmentjourney #marketanalysisinnovation #realworldevidence #diseasenavigator

𝐏𝐡𝐚𝐫𝐦𝐚 𝐋𝐚𝐮𝐧𝐜𝐡 𝐑𝐞𝐚𝐝𝐢𝐧𝐞𝐬𝐬 𝐂𝐡𝐞𝐜𝐤𝐥𝐢𝐬𝐭 Leading pharma-product launchers begin building their team as early as 24 months before launch. They often start with external-facing medical and market-access roles so that they can begin engaging with key stakeholders to derive valuable insights and create excitement about their new products. Furtheremore successful launchers invest early to build deep understanding of the competitors and their disease areas, which helps them judge how to position their drugs among the therapies available. Similarly, they draw on a wide range of data sources to make rigorous assessments of how competitors, providers, patients, and payers are likely to react to their new product. Launches are complex, successful companies build detailed road maps for their launches. In the slides it's a checklist on how to prepare for your launch. Please contact ATACANA GROUP Inc. for strategic support on your upcoming product launch! Also, comment below if you would like to get the brand plan outline and follow me to learn more about the pharmaceutical industry: https://lnkd.in/eUSfJJ3f Thank you for reading until here! 😊 #strategy #pharmaceuticals #productlaunch #biotech

How can we spread, scale & sustain life-saving treatments for disease? Moving #evidencebased therapies for cardiovascular-kidney-metabolic (#CKM) into action could be easier if partners come together. Read about what clinical researchers, payers, funders, journal editors, association, quality, and pharmaceutical industry leaders had to say about #knowledgetranslation at the DCRI’s #Implementation Summit. https://duke.is/imp-summit

Did you know… 🌍 There are now around 4.59 billion social media users globally 📱 90% of 18-24-year-olds and 60% of doctors acknowledge the impact of social media on healthcare quality 🌐 72% of internet users search for health information online Here are some of our bold predictions for the future… 🎯 Health data could influence the type of advertisements you receive. 🧠 Mental health issues might be diagnosed through the tone and usage patterns on your social media platforms. 🎮 Gamification and interactive content will enhance engagement and education for patients. 🔗 Social media platforms may in time be linked with electronic health record (EHR) systems. Explore these topics and more by listening to our latest trending health episode with Nico Renner from Roche. Already looking forward to next time, Nico, and seeing who was right about the predictions! 🚀 👇 👇 👇

💡 𝐒𝐡𝐚𝐩𝐢𝐧𝐠 𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰'𝐬 𝐏𝐡𝐚𝐫𝐦𝐚 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞: 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐋𝐞𝐚𝐝𝐞𝐫𝐬 At our 4x4 Innovation Meet on June 20, 2024, industry leaders, including Mike Rea, CEO of IDEA Pharma, shared insights on transformative strategies in pharmaceutical development. 🔹𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐄𝐚𝐫𝐥𝐲-𝐏𝐡𝐚𝐬𝐞 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧: A key discussion was the importance of implementing an appropriate market strategy from the start of drug development. Traditionally, early clinical trials focus on safety and efficacy. However, as Mike Rea showed with the Cymbalta case study, aligning these phases with market needs can increase commercial success and relevance. This makes market adoption smoother and more effective. 🔹𝐑𝐞𝐝𝐞𝐟𝐢𝐧𝐢𝐧𝐠 𝐑&𝐃 𝐒𝐮𝐜𝐜𝐞𝐬𝐬 𝐌𝐞𝐭𝐫𝐢𝐜𝐬: We also examined the need to change how we measure R&D success. Instead of only aiming for regulatory approval, the industry should use metrics that predict long-term market success and impact on patients. This ensures that new medicines are not only approved, but also successful and beneficial to consumers. These discussions provide important guidance for the strategic positioning of new products in a competitive market. Join us 𝐭𝐨𝐦𝐨𝐫𝐫𝐨𝐰 for the next 4x4 Innovation Meet to explore the latest developments across various industries: https://lnkd.in/gse8rcyA #PharmaInnovation #DrugDevelopment #4x4InnovationMeet #Pharmaceuticals #HealthcareInnovation #BusinessStrategy #MarketStrategy Magnus Hakvåg, 🔑Maria Boicova-Wynants Donal O'Connell; Sanaz Javadi Farahzadi; Dr. Dominique Christ; Dr. Claas Gerding-Reimers; Erdem KAYA; Archana Pandit; Udo Gennari; Priggya Arora; Shalini Sitaraman Menezes; Magda Voltolini; Ivan Gauci; Mustafa Cakir, RTTP, QPIP, Bastian Best; Dr. Jörn Plettig; Martin Schlosser; Henry K.H. Wang; Philipp Hammans; David Perkins — Software Patent Expert; Mário Castro Marques; David Durand; David Kalow; Dr. Benjamin DELSOL (PhD, LL.M); Stefan Brehm; Bastian July; Ines Duhanic, LL.M. (Stockholm); Amr Eldakak; Matthew Wahlrab; Rich McDonnell; Bruce Vojak; Christian Behr; Sam Bergstrom

Finding multiple use cases for your R&D investment plays a large role in de-risking your investment AND delivering a Return on Investment (ROI). Pharma, it turns out, has publicly available datasets that justify this conclusion. The data shows that thinking broadly about use case for a new compound is a critical component of an overall strategy for managing risk early in the investment phase. In pharma, early testing to find potential treatment indications for the compound gives you a number of 'shots on goal' as you look to spend over $1B to move your compound through clinical trials. When we investigated Roche, we saw that each New Molecule Entity (NME), as Roche defines them, had, on average, 7.5 indications and treatment modalities for each NME over our ten-year period. First, NME submissions for clinical trials were heavily biased towards oncology (see comment for our graph). When the first indication was not oncology, the majority of the time oncology was the second indication. This strategy outperforms others over the long run. Based on these observations, we can accurately predict Roche's next investments by knowing which phases of clinical trials it prefers. If you like insights like this, join us weekly at the 4x4 Innovation Group each Thursday @ 7AM Pacific where Martin Schweiger holds lively discussions with leading experts like Mike Rea on innovation strategies that ACTUALLY move the needle. Join us 𝐭𝐨𝐦𝐨𝐫𝐫𝐨𝐰 for the next 4x4 Innovation Meet to explore the latest developments across various industries: https://lnkd.in/gse8rcyA #innovationmanagement

Check out our latest podcast episode focussed on the critical topic of patient engagement within the life sciences industry. Tune in to discover: 🔹 Real-world examples of successful patient-centric initiatives 🔹 The impact of digital transformation on patient experiences 🔹 Future trends in patient engagement 🔹 Partnering with Compliance and what this means for the industry. We also have a guest contributor, Nico Renner (Patient Partnership Manager, Roche), who shares some fascinating insights from Roche on how they're reshaping how we connect with and empower patients. Give it a listen!

Diving Into Competitive Intelligence: The Key to Innovation in Pharma 🚀 Discover how Competitive Intelligence (CI) is revolutionizing pharmaceutical healthcare. Our latest blog explores CI's vital role in identifying market opportunities, enhancing R&D, and navigating complex regulatory landscapes. Learn about the challenges and successes of CI in driving groundbreaking innovations. As the pharma sector evolves, understanding the competitive landscape through CI is becoming indispensable for leading companies towards novel solutions and improved patient outcomes. Embrace insights and fuel innovation. Dive into the blog for a glimpse into the future of healthcare innovation. https://lnkd.in/d_XMTV94 #PharmaceuticalInnovation #CompetitiveIntelligence #HealthcareRevolution #InnovationThroughInsight

Last week, we shared insights on transformative strategies in pharmaceutical development. Join us on our next 4x4 Innovation Meet that is happening TODAY, 27 June 2024 at 22:00 (Singapore time). Attend here: https://lnkd.in/gd4apAEg #PharmaInnovation #DrugDevelopment #4x4InnovationMeet #Pharmaceuticals #HealthcareInnovation #BusinessStrategy #MarketStrategy